Pharmaceuticals News and Research

RSS

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

Ipsen announces today a partnership with Photocure, a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology.

27 Sep 2011

TPI revenue increases 48.9% to $95.2 million for fiscal year 2011

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the Fiscal Year 2011.

27 Sep 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Synta Pharmaceuticals Corp. announced that results of a Phase 1 study of ganetespib in combination with docetaxel in solid tumors were presented at the Annual Meeting of the European Society of Medical Oncology in Stockholm, Sweden.

27 Sep 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has successfully completed a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the proposed Phase III clinical study for COL-003, the Company's tamper-resistant, extended release oxycodone product utilizing its proprietary DETERx technology.

27 Sep 2011

Roundup: Patient dies after medical error during Calif. nurses strike; grocery workers ratify contract that had partially hinged on health care

Veteran nurses locked out of Alta Bates Summit Medical Center in Oakland said Sunday that the death of a patient due to a medical error by a replacement worker wouldn't have happened if they had been allowed to do their jobs. The hospital's management countered that it was a freak accident that could have happened at any time -- with or without the replacement nurses. At the center of the dispute is a cancer patient, a woman who has not been identified but whose tragic death on Saturday has inflamed an already tense labor dispute.

27 Sep 2011

Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting

Pacira Pharmaceuticals, Inc. today announced that the company's lead investigational product for postsurgical pain management, EXPAREL, was highlighted in the "Hot Topics in Plastic Surgery" panel at the annual scientific assembly of the American Society of Plastic Surgeons (ASPS) in Denver, Colo.

26 Sep 2011

Link between changes in malaria parasite and absorption of pharmaceutical compounds

Professor Max Petzold at the Nordic School of Public Health shows in a recent article a link between changes in the malaria parasite and the absorption of pharmaceutical compounds. Increased knowledge of the malaria parasite and the connection with the development of resistance may contribute to the development of new malaria treatments.

26 Sep 2011

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.

26 Sep 2011

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.

26 Sep 2011

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Isis files patent infringement lawsuit against Santaris for antisense drugs

Isis Pharmaceuticals, Inc. announced today it has filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp. in the United States District Court of the Southern District of California.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

'Time matters' in the fight against pulmonary hypertension

The Pulmonary Hypertension Association Europe (PHA EU) has launched ‘Time Matters’ a new campaign which encourages people with Pulmonary Hypertension (PH) and their friends and family to share hopes and dreams for the future in order to raise awareness of this deadly and rapidly progressive condition. By logging on to the website http://phtimematters.org and posting an entry, everybody can help the patient association take a step towards increased awareness and understanding of this devastating condition.

26 Sep 2011

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Regeneron Pharmaceuticals, Inc. today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.

26 Sep 2011

Primatene inhalers to be phased out this December: FDA

According to the Food and Drugs Administration (FDA), the Armstrong Pharmaceutical's Primatene mist inhaler will be discontinued on Dec. 31, and prescription inhalers are the only alternative to the over-the-counter asthma drug.

26 Sep 2011

First Radium-223 Chloride Phase III study in prostate cancer

Until recently, options for patients with bone metastases from advanced prostate cancer have been very limited. But now the first Phase III study of an alpha-pharmaceutical in these patients has shown that it can prolong survival significantly, according to research reported today (Saturday) at the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

Pharmaceuticals News and Research

Photocure, Ipsen partner to commercialise Hexvix for diagnosis of bladder cancer

TPI revenue increases 48.9% to $95.2 million for fiscal year 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Collegium completes Type A meeting with FDA for COL-003 Phase III chronic low back pain study

Roundup: Patient dies after medical error during Calif. nurses strike; grocery workers ratify contract that had partially hinged on health care

Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting

Link between changes in malaria parasite and absorption of pharmaceutical compounds

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Isis files patent infringement lawsuit against Santaris for antisense drugs

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

'Time matters' in the fight against pulmonary hypertension

Regeneron announces additional data from aflibercept Phase 3 trial on colorectal cancer

Primatene inhalers to be phased out this December: FDA

First Radium-223 Chloride Phase III study in prostate cancer

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence